Pentoxifylline inhibits transforming growth factor-beta signaling and renal fibrosis in experimental crescentic glomerulonephritis in rats

American Journal of Nephrology

Volumn 29, Issue 1, 2008, Pages 43-53

  Ng, Yee Yung ^a   Chen, Yung Ming ^b   Tsai, Tun Jun ^b   Lan, Xiao Ru ^c   Yang, Wu Chang ^a   Lan, Hui Y ^c  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Crescentic glomerulonephritis; Epithelial myofibroblast transition; Pentoxifylline; Renal fibrosis; Smads; Transforming growth factor beta

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN; PENTOXIFYLLINE; PHOSPHATE BUFFERED SALINE; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; UVOMORULIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; CRESCENTIC GLOMERULONEPHRITIS; DRUG ACTIVITY; DRUG EFFECT; EXPERIMENTAL MODEL; GLOMERULONEPHRITIS; GLOMERULUS BASEMENT MEMBRANE; IMMUNOHISTOCHEMISTRY; KIDNEY FIBROSIS; KIDNEY TUBULE CELL; MALE; MYOFIBROBLAST; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TREATMENT DURATION; UPREGULATION; WISTAR RAT;

ANIMALS; DISEASE MODELS, ANIMAL; FIBROSIS; GLOMERULONEPHRITIS; KIDNEY; MALE; MODELS, BIOLOGICAL; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITORS; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 48449106999     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000150600     Document Type: Article

References (28)

1. Tipping PG, Kitching AR, Cunningham MA, Holdsworth SR: Immunopathogenesis of crescentic glomerulonephritis. Curr Opin Nephrol Hypertens 1999;8:281-286.
2. Lin SL, Chen YM, Chiang WC, Tsai TJ, Chen WY: Pentoxifylline: a potential therapy for chronic kidney disease. Nephrology (Carlton) 2004;9:198-204.
3. Chen YM, Chien CT, Hu-Tsai MI, Wu KD, Tsai CC, Wu MS, Tsai TJ: Pentoxifylline attenuates experimental mesangial proliferative glomerulonephritis. Kidney Int 1999;56:932-943.
4. Wang W, Zolty E, Falk S, Basava V, Reznikov L, Schrier R: Pentoxifylline protects against endotoxin-induced acute renal failure in mice. Am J Physiol Renal Physiol 2006;291:F1090-F1095.
5. Chen YM, Ng YY, Lin SL, Chiang WC, Lan HY, Tsai TJ: Pentoxifylline suppresses renal tumour necrosis factor-alpha and ameliorates experimental crescentic glomerulonephritis in rats. Nephrol Dial Transplant 2004;19:1106-1115.
6. Lin SL, Chen YM, Chien CT, Chiang WC, Tsai CC, Tsai TJ: Pentoxifylline attenuated the renal disease progression in rats with remnant kidney. J Am Soc Nephrol 2002;13:2916-2929.
7. Demir E, Paydas S, Balal M, Kurt C, Sertdemir Y, Erken U: Effects of pentoxifylline on the cytokines that may play a role in rejection and resistive index in renal transplant recipients. Transplant Proc 2006;38:2883-2886.
8. Navarro JF, Mora C, Muros M, Garcia J: Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial. J Am Soc Nephrol 2005;16:2119-2126.
9. Chen YM, Lin SL, Chiang WC, Wu KD, Tsai TJ: Pentoxifylline ameliorates proteinuria through suppression of renal monocyte chemoattractant protein-1 in patients with proteinuric primary glomerular diseases. Kidney Int 2006;69:1410-1415.
10. Rodriguez-Moran M, Gonzalez-Gonzalez G, Bermudez-Barba MV, Medina de la Garza CE, Tamez-Perez HE, Martinez-Martinez FJ, Guerrero-Romero F: Effects of pentoxifylline on the urinary protein excretion profile of type 2 diabetic patients with microproteinuria: a double-blind, placebo-controlled randomized trial. Clin Nephrol 2006;66:3-10.
11. Ducloux D, Bresson-Vautrin C, Chalopin J: Use of pentoxifylline in membranous nephropathy. Lancet 2001;357:1672-1673.
12. Ng YY, Huang TP, Yang WC, Chen ZP, Yang AH, Mu W, Nikolic-Paterson DJ, Atkins RC, Lan HY: Tubular epithelial-myofibroblast transdifferentiation in progressive tubulointerstitial fibrosis in 5/6 nephrectomized rats. Kid Int 1998;54:864-876.
13. Lan HY, Mu W, Nikolic-Paterson DJ, Atkins RC: A novel, simple, reliable, and sensitive method for multiple immunoenzymed staining: use of microwave oven heating to block antibody crossreactivity and retrieve antigens. J Histochem Cytochem 1995;43:97-102.
14. Lan HY, Mu W, Tomita N, Huang XR, Li JH, Zhu HJ, Morishita R, Johnson RJ: Inhibition of renal fibrosis by gene transfer of inducible Smad7 using ultrasound-microbubble system in rat UUO model. J Am Soc Nephrol 2003;14:1535-1548.
15. Lan HY: Tubular epithelial-myofibroblast transdifferentiation mechanisms in proximal tubule cells. Curr Opin Nephrol Hypertens 2003;12:25-29.
16. Liu Y: Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol 2004;15:1-12.
17. Kalluri R, Neilson EG: Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 2003;112:1776-1784.
18. Nishitani Y, Iwano M, Yamaguchi Y, Harada K, Nakatani K, Akai Y, Nishino T, Shiiki H, Kanauchi M, Saito Y, Neilson EG: Fibroblast-specific protein 1 is a specific prognostic marker for renal survival in patients with IgAN. Kidney Int 2005;68:1078-1085.
19. Aresu L, Rastaldi MP, Scanziani E, Baily J, Radaelli E, Pregel P, Valenza F: Epithelial-mesenchymal transition (EMT) of renal tubular cells in canine glomerulonephritis. Virchows Arch 2007;45:1937-1942.
20. Jinde K, Nikolic-Paterson DJ, Huang XR, Sakai H, Kurokawa K, Atkins RC, Lan HY: Tubular phenotypic change in progressive tubulointerstitial fibrosis in human glomerulonephritis. Am J Kidney Dis 2001;38:761-769.
21. Ng YY, Fan JM, Mu W, Nikolic-Paterson DJ, Yang WC, Huang TP, Atkins RC, Lan HY: Glomerular epithelial-myofibroblast transdifferentiation in the evolution of glomerular crescent formation. Nephrol Dial Transplant 1999;14:1860-1872.
22. Lin SL, Chen RH, Chen YM, Chiang WC, Lai CF, Wu KD, Tsai TJ: Pentoxifylline attenuates tubulointerstitial fibrosis by blocking Smad3/4-activated transcription and profibrogenic effects of connective tissue growth factor. J Am Soc Nephrol 2005;16:2702-2713.
23. Strutz F, Heeg M, Kochsiek T, Siemers G, Zeisberg M, Müller GA: Effects of pentoxifylline, pentifylline and gamma-interferon on proliferation, differentiation, and matrix synthesis of human renal fibroblasts. Nephrol Dial Transplant 2000;15:1535-1546.
24. Wang W, Koka V, Lan HY: Transforming growth factor-beta and Smad signalling in kidney diseases. Nephrology (Carlton) 2005;10:48-56.
25. Ka SM, Huang XR, Lan HY, Tsai PY, Yang SM, Shui HA, Chen A: Smad7 gene therapy ameliorates an autoimmune crescentic glomerulonephritis in mice. J Am Soc Nephrol 2007;18:1777-1788.
26. Fan JM, Ng YY, Hill PA, Nikolic-Paterson DJ, Mu W, Atkins RC, Lan HY: Transforming growth factor-beta regulates tubular epithelial-myofibroblast transdifferentiation in vitro. Kidney Int 1999;56:1455-1467.
27. Li JH, Zhu HJ, Huang XR, Lai KN, Johnson RJ, Lan HY: Smad7 inhibits fibrotic effect of TGF-Beta on renal tubular epithelial cells by blocking Smad2 activation. J Am Soc Nephrol 2002;13:1464-1472.
28. Fan JM, Huang XR, Ng YY, Nikolic-Paterson DJ, Mu W, Atkins RC, Lan HY: Interleukin-1 induces tubular epithelial-myofibroblast transdifferentiation through a transforming growth factor-beta1-dependent mechanism in vitro. Am J Kidney Dis 2001;37:820-831.